All Releases
 |
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
Jun 30, 2008
|
13.5 KB |
|
| |
RICHMOND, Calif., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)). The data suggest t...
|
|
Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Jun 18, 2008
|
12.6 KB |
|
| |
SAN DIEGO, June 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today at the 2008 BIO International Convention that it has exercised its option to obtain a commercial license to zinc finger technology from Richmond, Calif.-based Sangamo Bio...
|
|
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Jun 8, 2008
|
19.6 KB |
|
| |
SAN FRANCISCO, June 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM) program at the 68th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, ...
|
|
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Jun 6, 2008
|
12.1 KB |
|
| |
SAN FRANCISCO, June 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the completion of patient enrollment into its Phase 2 clinical trial (SB-509-701) in subjects with moderate to severe diabetic neuropathy. Additionally, based upon positive initial data, the company plans to expand ...
|
|
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
Jun 5, 2008
|
11.8 KB |
|
| |
INDIANAPOLIS and RICHMOND, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the successful completion of research milestones as part of their joint Research and Commercial License Agreement. These milestones represent the successful application o...
|
|
Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
May 29, 2008
|
8.2 KB |
|
| |
RICHMOND, Calif., May 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on Sangamo's diabetic neuropathy programs at 1:40 p.m. (ET) on Friday, June 6, 2008, at the Canaccord Adams Diabetes and Obesity Conferenc...
|
|
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
May 19, 2008
|
12.3 KB |
|
| |
MIAMI, May 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from a Phase 1 clinical trial of a zinc finger DNA-binding protein activator of vascular endothelial growth factor (ZFP-VEGF) in subjects with critical limb ischemia (CLI). The data demonstrate that...
|
|
Sangamo BioSciences to Present at the Citi Investment Research Global Healthcare Conference
May 14, 2008
|
8.2 KB |
|
| |
RICHMOND, Calif., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:30 a.m. (ET) on...
|
|
Sangamo BioSciences to Present at the 7th Annual JMP Securities Research Conference
May 13, 2008
|
8.2 KB |
|
| |
RICHMOND, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:00 p.m. (ET) on...
|
|
Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
May 7, 2008
|
8.2 KB |
|
| |
RICHMOND, Calif., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 7:40 p.m. (ET) on T...
|
|
Sangamo BioSciences Reports First Quarter 2008 Financial Results
Apr 30, 2008
|
16.5 KB |
|
| |
RICHMOND, Calif., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2008 financial results and accomplishments.
For the first quarter ended March 31, 2008, Sangamo reported a consolidated net loss of $8.0 million, or $0.20 per share, compared to a net loss of $...
|
|
Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
Apr 28, 2008
|
10.8 KB |
|
| |
RICHMOND, Calif., April 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the nomination of Thomas G. Wiggans to the company's Board of Directo...
|
|
Sangamo BioSciences Announces First Quarter Conference Call and Webcast
Apr 23, 2008
|
8.7 KB |
|
| |
RICHMOND, Calif., April 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2008 financial results on Wednesday, April 30, 2008, after the market closes. The press release will be followed by a conference call at 2:00 p.m. PT, which will ...
|
|
Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Apr 15, 2008
|
12.6 KB |
|
| |
SAN DIEGO, April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. The data were presented i...
|
|
Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Apr 7, 2008
|
9.7 KB |
|
| |
RICHMOND, Calif., April 7, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provide a non-exclusive, worldwide...
|
|
Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines
Mar 24, 2008
|
12.3 KB |
|
| |
ST. LOUIS and RICHMOND, Calif., March 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) and Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication of data demonstrating the use of Sangamo's zinc finger DNA-binding protein nucleases (ZFNs(TM)) in a new approach for rapid generation ...
|
|
Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
Mar 11, 2008
|
8.2 KB |
|
| |
RICHMOND, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 9:30 a.m. (ET) o...
|
|
Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
Feb 27, 2008
|
9.3 KB |
|
| |
RICHMOND, Calif., Feb 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that it has entered into a second Research and License Agreement with Genentech, Inc. expanding on the original agreement to include additional targets for potential improvement of production cell lines using San...
|
|
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
Feb 12, 2008
|
10.8 KB |
|
| |
INDIANAPOLIS, and RICHMOND, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of a key research milestone as part of their joint Research and Commercial License Agreement. This milestone represents the successful applicat...
|
|
Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Feb 5, 2008
|
18.0 KB |
|
| |
RICHMOND, Calif., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported 2007 fourth quarter and year-end financial results and accomplishments and provided an outlook for 2008.
For the fourth quarter ended December 31, 2007, Sangamo reported a consolidated net loss of $6.7 million...
|
|
|
